<code id='875AF11D51'></code><style id='875AF11D51'></style>
    • <acronym id='875AF11D51'></acronym>
      <center id='875AF11D51'><center id='875AF11D51'><tfoot id='875AF11D51'></tfoot></center><abbr id='875AF11D51'><dir id='875AF11D51'><tfoot id='875AF11D51'></tfoot><noframes id='875AF11D51'>

    • <optgroup id='875AF11D51'><strike id='875AF11D51'><sup id='875AF11D51'></sup></strike><code id='875AF11D51'></code></optgroup>
        1. <b id='875AF11D51'><label id='875AF11D51'><select id='875AF11D51'><dt id='875AF11D51'><span id='875AF11D51'></span></dt></select></label></b><u id='875AF11D51'></u>
          <i id='875AF11D51'><strike id='875AF11D51'><tt id='875AF11D51'><pre id='875AF11D51'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          knowledge

          author:fashion    - browse:669
          The New York Stock Exchange's screen displays a logo of Johnson & Johnson — pharma coverage from STAT
          AP/Richard Drew

          Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development. 

          The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry. 

          advertisement

          Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          entertainment